L3VLUP
ProSign in

BIIB · AMGN in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

BIIBAMGN
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • BIIB
  • AMGN
010203040202120222023202420252026
Holders and value by quarter
QuarterBIIBAMGN
Q3 202025 holders, $5.1bn16 holders, $16.3bn
Q4 202022 holders, $4.6bn19 holders, $14.0bn
Q1 202118 holders, $4.7bn16 holders, $14.5bn
Q2 202125 holders, $5.4bn23 holders, $13.8bn
Q3 202123 holders, $3.3bn24 holders, $11.6bn
Q4 202125 holders, $3.7bn21 holders, $10.4bn
Q1 202229 holders, $3.7bn23 holders, $9.9bn
Q2 202225 holders, $3.4bn28 holders, $9.7bn
Q3 202233 holders, $5.2bn21 holders, $7.9bn
Q4 202228 holders, $5.0bn24 holders, $9.3bn
Q1 202330 holders, $5.1bn22 holders, $8.4bn
Q2 202323 holders, $4.4bn26 holders, $7.4bn
Q3 202321 holders, $2.9bn26 holders, $8.7bn
Q4 202317 holders, $2.8bn24 holders, $8.4bn
Q1 202416 holders, $2.5bn25 holders, $6.7bn
Q2 202414 holders, $2.5bn20 holders, $8.0bn
Q3 202417 holders, $2.6bn21 holders, $8.8bn
Q4 202420 holders, $2.6bn20 holders, $8.2bn
Q1 202522 holders, $2.4bn25 holders, $12.0bn
Q2 202520 holders, $2.5bn20 holders, $10.2bn
Q3 202521 holders, $2.8bn17 holders, $10.4bn
Q4 202520 holders, $3.9bn19 holders, $18.0bn
Q1 202616 holders, $3.9bn15 holders, $21.4bn
Q2 202612 holders, $5.8bn23 holders, $24.9bn
BIIB

Biogen Inc

Holders
20
Reported value
$3.9bn
Buyers
12
Sellers
25

Breadth -13 among 92 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
AMGN

Amgen Inc

Holders
19
Reported value
$18.0bn
Buyers
13
Sellers
22

Breadth -9 among 92 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q4 2025

Among the 32 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only BIIB (13)

AQR Capital Management LLC, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Freestone Grove Partners LP, Glenview Capital Management LLC, Hudson Bay Capital Management LP, MFS Investment Management, Millennium Management LLC, PDT Partners LLC, Point72 Asset Management LP, Renaissance Technologies LLC, Wellington Management Group LLP, Winton Group Ltd

Only AMGN (12)

AllianceBernstein LP, ARK Investment Management LLC, Capital Research Global Investors, Capital World Investors, Dodge & Cox, Holocene Advisors LP, Invesco Ltd, Janus Henderson Group Ltd, Neuberger Berman Group LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Verition Fund Management LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →